ULBI 最新10-Q变化
将 ULBI 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-07 与上一份 10-Q · 2026-05-08
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +33 | −18 | ~11 | 19 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~4 | 7 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、法律诉讼、风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-07
Operating income for the three-month period ended June 30, 2026, was $3,437, or 7.2% of revenues, compared to $2,256, or 4.6% of revenues, for the year-earlier period. The increase in operating income primarily resulted from the favorable product mix for our Battery & Energy Products and Communicati…
Other expense for the second quarter of 2026 was $451 compared to $1,143 for the year-earlier quarter. The decrease for the 2026 period primarily reflects lower interest expense for the financing of our Electrochem acquisition with the continued paydown of the related term loan, the current period e…
Net income attributable to Ultralife Corporation was $2,543, or $0.15 per share – basic and diluted, for the three-month period ended June 30, 2026, compared to $879, or $0.05 per share – basic and diluted, for the three-month period ended June 30, 2025.
Adjusted EBITDA, defined as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing operations…
We remain intently focused on converting our long-term new product development efforts into revenue, maintaining a strong focus on operational efficiency initiatives to improve our gross margins and advancing vertical integration in the oil & gas segment. We believe these improvements, along with ex…
相对上期删除的文字 · 来源:10-Q · 2026-05-08
Operating (loss) income for the three-month period ended March 31, 2026, was ($215), or (0.5)% of revenues, compared to $3,399, or 6.7% of revenues, for the year-earlier period. The decrease in operating income primarily resulted from the declines in revenue and gross margin and the increase in oper…
Net (loss) income attributable to Ultralife Corporation was ($451), or ($0.03) per share – basic and diluted, for the three-month period ended March 31, 2026, compared to $1,865, or $0.11 per share – basic and diluted, for the three-month period ended March 31, 2025.
Adjusted EBITDA, defined as net (loss) income attributable to Ultralife Corporation before net interest expense, (benefit) provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing ope…
We remain intently focused on improving manufacturing efficiencies at our Newark, NY facility, particularly as we ramp up production of new products, in order to increase the gross margin of Battery & Energy Products, and on driving Communications Systems orders. These improvements, along with execu…
Revenues. Consolidated revenues for the three-month period ending March 31, 2026, were $47,445, a decrease of $3,301, or 6.5%, from $50,746 for the three-month period ended March 31, 2025. Overall, commercial sales decreased 5.5% and government/defense sales decreased 8.2%.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议